PMID- 16324685 OWN - NLM STAT- MEDLINE DCOM- 20060907 LR - 20220310 IS - 0006-3223 (Print) IS - 1873-2402 (Electronic) IS - 0006-3223 (Linking) VI - 59 IP - 12 DP - 2006 Jun 15 TI - 3,4-Methylenedioxymethamphetamine in adult rats produces deficits in path integration and spatial reference memory. PG - 1219-26 AB - BACKGROUND: +/-3,4-Methylenedioxymethamphetamine (MDMA) is a recreational drug that causes cognitive deficits in humans. A rat model for learning and memory deficits has not been established, although some cognitive deficits have been reported. METHODS: Male Sprague-Dawley rats were treated with MDMA (15 mg/kg x 4 doses) or saline (SAL) (n = 20/treatment group) and tested in different learning paradigms: 1) path integration in the Cincinnati water maze (CWM), 2) spatial learning in the Morris water maze (MWM), and 3) novel object recognition (NOR). One week after drug administration, testing began in the CWM, then four phases of MWM, and finally NOR. Following behavioral testing, monoamine levels were assessed. RESULTS: +/-3,4-Methylenedioxymethamphetamine-treated rats committed more CWM errors than did SAL-treated rats. +/-3,4-Methylenedioxymethamphetamine-treated animals were further from the former platform position during each 30-second MWM probe trial but showed no differences during learning trials with the platform present. There were no group differences in NOR. +/-3,4-Methylenedioxymethamphetamine depleted serotonin in all brain regions and dopamine in the striatum. CONCLUSIONS: +/-3,4-Methylenedioxymethamphetamine produced MWM reference memory deficits even after complex learning in the CWM, where deficits in path integration learning occurred. Assessment of path integration may provide a sensitive index of MDMA-induced learning deficits. FAU - Able, Jessica A AU - Able JA AD - Neuroscience Graduate Program, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. FAU - Gudelsky, Gary A AU - Gudelsky GA FAU - Vorhees, Charles V AU - Vorhees CV FAU - Williams, Michael T AU - Williams MT LA - eng GR - K01 DA014269-05/DA/NIDA NIH HHS/United States GR - R01 DA021394-02/DA/NIDA NIH HHS/United States GR - R01 DA006733-16/DA/NIDA NIH HHS/United States GR - R01 DA007427-16/DA/NIDA NIH HHS/United States GR - DA006733/DA/NIDA NIH HHS/United States GR - K01 DA014269/DA/NIDA NIH HHS/United States GR - R01 DA021394/DA/NIDA NIH HHS/United States GR - DA007427/DA/NIDA NIH HHS/United States GR - R01 DA006733/DA/NIDA NIH HHS/United States GR - DA014269/DA/NIDA NIH HHS/United States GR - R01 DA007427/DA/NIDA NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20051201 PL - United States TA - Biol Psychiatry JT - Biological psychiatry JID - 0213264 RN - 0 (Hallucinogens) RN - 451W47IQ8X (Sodium Chloride) RN - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine) SB - IM MH - Analysis of Variance MH - Animals MH - Behavior, Animal/*drug effects MH - Cognition/drug effects MH - Hallucinogens/*pharmacology MH - Learning/*drug effects MH - Male MH - Maze Learning/drug effects MH - Memory Disorders/*chemically induced MH - Memory, Short-Term/drug effects MH - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology MH - Rats MH - Rats, Sprague-Dawley MH - Recognition, Psychology/drug effects MH - Sodium Chloride/administration & dosage MH - Spatial Behavior/*drug effects MH - Time Factors PMC - PMC2888296 MID - NIHMS207867 EDAT- 2005/12/06 09:00 MHDA- 2006/09/08 09:00 PMCR- 2010/06/21 CRDT- 2005/12/06 09:00 PHST- 2005/05/13 00:00 [received] PHST- 2005/08/26 00:00 [revised] PHST- 2005/09/12 00:00 [accepted] PHST- 2005/12/06 09:00 [pubmed] PHST- 2006/09/08 09:00 [medline] PHST- 2005/12/06 09:00 [entrez] PHST- 2010/06/21 00:00 [pmc-release] AID - S0006-3223(05)01105-4 [pii] AID - 10.1016/j.biopsych.2005.09.006 [doi] PST - ppublish SO - Biol Psychiatry. 2006 Jun 15;59(12):1219-26. doi: 10.1016/j.biopsych.2005.09.006. Epub 2005 Dec 1.